JP Patent

JP2025523020A — 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与

Assigned to Genentech Inc · Expires 2025-07-17 · 1y expired

What this patent protects

本発明は、抗フラグメント結晶性受容体様５（ＦｃＲＨ５）／抗分化抗原群３（ＣＤ３）二重特異性抗体を、多発性骨髄腫などのがんの処置のために投与する方法を提供する。【選択図】なし

USPTO Abstract

本発明は、抗フラグメント結晶性受容体様５（ＦｃＲＨ５）／抗分化抗原群３（ＣＤ３）二重特異性抗体を、多発性骨髄腫などのがんの処置のために投与する方法を提供する。【選択図】なし

Drugs covered by this patent

Inlyta (Axitinib) · Pfizer

Patent Metadata

Patent number: JP2025523020A
Jurisdiction: JP
Classification: —
Expires: 2025-07-17
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.